Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
about
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung CancerA meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancerPLGA nanoparticle encapsulation reduces toxicity while retaining the therapeutic efficacy of EtNBS-PDT in vitroRegistered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsDDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer.Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.Molecular chess? Hallmarks of anti-cancer drug resistanceUnderstanding why aspirin prevents cancer and why consuming very hot beverages and foods increases esophageal cancer risk. Controlling the division rates of stem cells is an important strategy to prevent cancer.Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumorsUnique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA constructNF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations.IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.Type I insulin-like growth factor receptor signaling in hematological malignancies.Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinomaStemness and plasticity of lung cancer cells: paving the road for better therapy.The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer.CD44 silencing decreases the expression of stem cell-related factors induced by transforming growth factor β1 and tumor necrosis factor α in lung cancer: Preliminary findings.IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells.Understanding and targeting resistance mechanisms in NSCLC.Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment.Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1α.
P2860
Q26740210-F9A05191-D073-4E37-925F-8568A7C0E105Q26998677-8C72BE0E-B29C-45A0-ADEC-5CF51CDEC6AEQ27348681-6D59A5F4-56A9-43C8-BD51-0A4C8372D553Q28603408-7D2E6F46-0921-4BBC-9C11-87EC6CF2451DQ33775108-09FB6242-DC65-4EBB-BC30-77E5A1F6B5B0Q35606589-D00B0DF0-D18B-4787-B9FE-450339AE1A59Q35833023-9C44238C-28C8-428B-B975-B621217C1861Q36021018-6A06704E-0C12-4AC8-94A3-3F3F0DE2F4F8Q36240941-C294EA97-CD31-49AC-B5FE-D06C007C19FCQ36352613-50C02C33-F308-4800-A3FB-539CF1F4A147Q36401950-39858203-C298-4B5F-BE5F-5C53FD3B5B23Q36772120-EEFD4DEA-A54B-4613-9057-9A8D9AC7950CQ37059663-65E574E2-30A5-47E1-93A0-E30BD4AAC591Q37173070-4AC71E69-BF9D-4A3D-A06D-34BD9DE74D1DQ37688169-49157FF7-E83F-48AC-B7B6-CD18457257D7Q37696166-BF4C78B6-933F-4771-B531-2C79C6718268Q37702186-545635DE-3928-4DD5-8636-0159336F1378Q37708801-EF4CBFDC-574F-4D13-9B60-EE20BB14780AQ38229007-721AE2B1-A2B1-4D22-849C-1645B6D53642Q38296670-8ABDA301-9C35-4A03-BA00-FB1835101BDDQ38705954-D6C57F98-2EF5-4C87-A8AA-BF634FBA81E2Q38707122-13D0E4B6-E031-44C4-BBD9-618A0FAE0D48Q38745430-AD48F37A-9ACF-487C-99B3-B39576971094Q38830254-DCFF7641-C702-4F61-B022-96254D43F475Q38968478-406569F1-FBDE-4EB3-9868-07F71EA99A4BQ39131033-196A0657-8869-44BA-B96F-430EAA0F454CQ41615232-2935F56A-AE5B-4C10-8FCF-8F77BEFA3895Q46915997-DCEC10B8-C930-46BC-9E35-9CCAD105D094Q47154025-E21013E1-81EF-437B-A2E6-2CFC194EF0A2Q47769995-C3761F9D-98E8-4E25-8168-E14E513F08B6Q52571378-EFD8E0F8-AFA8-4A68-8624-E821C57FE5E3Q55260378-7577DAF8-B310-489E-B262-6A9197989CDE
P2860
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@en
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@nl
type
label
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@en
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@nl
prefLabel
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@en
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@nl
P2093
P2860
P1433
P1476
Hypoxia increases gefitinib-re ...... like growth factor 1 receptor.
@en
P2093
Akiko Murakami
Fumiaki Koizumi
Fumiyuki Takahashi
Hiroyuki Moriyama
Isao Kobayashi
Kazuhisa Takahashi
Ken Tajima
Kunihiko Minakata
Mariko Moriyama
Motoyasu Kato
P2860
P304
P356
10.1371/JOURNAL.PONE.0086459
P407
P577
2014-01-28T00:00:00Z